The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABVC | +348.48% | -92.6% | -40.59% | -87% |
| S&P | +19.61% | +98.99% | +14.75% | +489% |
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.08M | -178.0% |
| Gross Margin | -9020.85% | -2340.8% |
| Market Cap | $37.78M | 305.1% |
| Market Cap / Employee | $1.99M | 0.0% |
| Employees | 19 | 0.0% |
| Net Income | -$2.33M | -83.3% |
| EBITDA | -$2.21M | -129.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.08M | 44.9% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.18M | -22.6% |
| Short Term Debt | $2.14M | -14.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -19.80% | 71.7% |
| Return On Invested Capital | -248.40% | -106.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.89M | 13.9% |
| Operating Free Cash Flow | -$0.89M | 13.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.99 | 0.90 | 1.61 | 6.33 | 513.02% |
| Price to Sales | 16.63 | 16.06 | 31.21 | 98.88 | 53.91% |
| Price to Tangible Book Value | 0.99 | 0.90 | 1.61 | 6.33 | 513.02% |
| Enterprise Value to EBITDA | 175.62 | -64.29 | -35.55 | -19.12 | 80.29% |
| Return on Equity | -90.9% | -97.4% | -27.0% | -39.9% | -84.52% |
| Total Debt | $2.75M | $3.20M | $2.99M | $2.31M | -15.46% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
